Catalyst
Slingshot members are tracking this event:
Results from Phase 3 ARIEL3 maintenance treatment trial of rucaparib in advanced ovarian cancer patients will be highlighted at ESMO
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CLVS | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 07, 2017
Occurred Source:
http://phx.corporate-ir.net/phoenix.zhtml?c=247187&p=irol-newsArticle&ID=2299355
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Rucaparib, Advanced Ovarian Cancer
